# A Study to Assess the Efficacy and Safety of Ruxolitinib Cream in Children With Atopic Dermatitis (TRuE-AD3)

> **NCT04921969** · PHASE3 · COMPLETED · sponsor: **Incyte Corporation** · enrollment: 330 (actual)

## Conditions studied

- Atopic Dermatitis

## Interventions

- **DRUG:** Ruxolitinib
- **DRUG:** Vehicle Cream

## Key facts

- **NCT ID:** NCT04921969
- **Lead sponsor:** Incyte Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-07-19
- **Primary completion:** 2023-05-10
- **Final completion:** 2024-04-08
- **Target enrollment:** 330 (ACTUAL)
- **Last updated:** 2025-03-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04921969

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04921969, "A Study to Assess the Efficacy and Safety of Ruxolitinib Cream in Children With Atopic Dermatitis (TRuE-AD3)". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04921969. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*